Medical Oncology, Internal Medicine
Welcome,         Profile    Billing    Logout  
 5 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kim, Jee Hyun
postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active, not recruiting
3
368
Europe, US, RoW
Abemaciclib, Fulvestrant, Placebo
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasm, Neoplasm Metastasis
02/24
02/26
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Recruiting
3
860
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
04/24
08/27
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Recruiting
3
650
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
10/24
06/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
OPTIMAL, NCT03315364: Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy

Active, not recruiting
2/3
549
Europe, RoW
Oral paclitaxel, Liporaxel®, Paclitaxel injection, Taxol®
Daehwa Pharmaceutical Co., Ltd.
Recurrent or Metastatic Breast Cancer
01/24
03/24
BRISK, NCT05904457: A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer

Recruiting
2
32
RoW
bevacizumab, onbevzi, erlotinib, eltinib
Asan Medical Center, Korean Cancer Study Group, Boryung Pharmaceutical Co., Ltd
Solid Tumors, Advanced Solid Tumors, Metastatic Cancer
01/25
01/26
Decrescendo, NCT04675827: De-escalation Adjuvant Chemo in HER2+/ER-/Node-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo & Dual HER2 Blockade

Suspended
2
1065
Europe, RoW
Pertuzumab and tratuzumab fixed dose combination, Adjuvant pertuzumab + trastuzumab FDC SC for 14 cycles, Fixed-dose combination of Perjeta and Herceptin for subcutaneous injection for 14 cycles, Trastuzumab emtansine, Adjuvant T-DM1
Jules Bordet Institute, Breast International Group, Hoffmann-La Roche, International Drug Development Institute, Institut Curie
HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, Node-negative Breast Cancer
06/27
03/29
ELECTRA, NCT05386108: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer

Recruiting
1/2
106
Europe, US, RoW
Elacestrant, ELA-0121, Abemaciclib, Verzenio
Stemline Therapeutics, Inc.
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
12/25
12/25
NCT03763604: Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Available
N/A
Europe, Canada, RoW
Abemaciclib, LY2835219
Eli Lilly and Company
Metastatic Breast Cancer
 
 
KOSMOS-II, NCT05525858: KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II

Recruiting
N/A
1000
RoW
Alectinib, Alecensa, Atezolizumab, Tecentriq, Erlotinib, Tarceva, Trastuzumab + Pertuzumab, Herceptin + Perjeta, Trastuzumab emtansine, Kadcyla, Vemurafenib, Zelboraf, Bevacizumab + Erlotinib, Avastin + Tarceva, Entrectinib, Rozlytrek, Pralsetinib, Gavreto
Seoul National University Bundang Hospital, Korean Cancer Study Group, Roche Pharma AG
Solid Tumor, Advanced Solid Tumor, Metastatic Cancer
09/25
09/25

Download Options